Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulsatile high-dose sunitinib versus TAS-102 in metastatic colorectal cancer
NL-OMON53126Phase 2Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in colorectal adenocarcinoma and colorectal cancer (CRC) comparing Sunitinib with TAS-102 (2 arms). Primary endpoint: Progression-free survival. Started Nov 2019; status: recruiting.
02
Drugs
sunitinibtrifluridine + tipiracil
03
Conditions
colorectal adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON53126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53126.